



Bristol-Myers Squibb & Pfizer Australia

EVOLVING ANTICOAGULATION IN PRIMARY CARE

Name: _____

QI&CPD/ACRRM no.: _____

Contact email: _____

Contact telephone: _____

REINFORCING ACTIVITY

Thank you for attending the 2018 Thrombo 360 meeting *Evolving Anticoagulation in Primary Care*, Active Learning Module (ALM). The RACGP/ACRRM criteria of an ALM require you to complete the predisposing and reinforcing activities in addition to participating on the day. Once all requirements have been met, you will be awarded 40 Category 1 QI&CPD points or 30 PRPD points.

Please complete and email or fax back this activity to info@elixir.net.au; Fax: 02 8212-8900. We also advise you to keep the completed copy on file for potential future audit purposes.

ACTIVITY

The aim of this reinforcing activity is to encourage you to reflect on your clinical practice in the context of the education you have participated in.

MANAGING PATIENTS WITH COAGULATION DISORDERS

During the 2–3 weeks following the meeting, can you recall a challenging NVAf or DVT/PE presentation that you encountered? If not, please consider a 'hypothetical patient' based on your clinical experience. Please reflect on what you learnt at the meeting, and consider how this would impact on your management of patients with NVAf or DVT/PE by answering the following questions:

1. **What may make the decision-making or diagnosis of this case, or cases that you have seen recently, a challenge?**

2. **How could the management of your challenging patients be impacted as a result of attending this meeting?**

3. **Can you recall some specific techniques learnt or knowledge gained during the ALM that you did or would employ to assist you in managing such patients?**



Bristol-Myers Squibb & Pfizer Australia

EVOLVING ANTICOAGULATION IN PRIMARY CARE

4. ***Please list the 4 most important learning outcomes you gained from the meeting that assisted /would assist you in managing challenging patients with NVAf or DVT/PE?***

- 1.
- 2.
- 3.
- 4.

5. ***Have you instituted any changes in your clinical practice with regard to screening for NVAf as a result of attending the meeting, or do you intend to? Please describe.***

6. ***Is there anything else you learnt at the meeting that would impact in a general sense with your management of patients with either NVAf or DVT/PE? For example, any other treatment approaches adopted?***

**PLEASE SCAN/EMAIL OR FAX BACK THIS FORM TO ELIXIR HEALTHCARE EDUCATION AT
info@elixir.net.au; FAX: (02) 8212 8900**

NVAf: Non-valvular atrial fibrillation; DVT: Deep vein thrombosis; PE: Pulmonary embolism.

Evolving Anticoagulation in Primary Care, is an educational program supported by Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, Level 2, 4 Nexus Court, Mulgrave VIC 3170, Pfizer PFE Australia Pty Ltd., Sydney, Australia, and developed by Elixir Healthcare Education Pty Limited, ABN 36 092 185 665, Level 32, 101 Miller Street, North Sydney NSW 2060. © Copyright 2018 Pfizer-Bristol-Myers Squibb Alliance and Elixir Healthcare Education Pty Limited. BMS-18-023.5/02/18.

Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association. In line with the Medicines Australia Code of Conduct, this educational meeting is only open to healthcare providers. Guests or family members cannot be accommodated.

The Pfizer-Bristol-Myers Squibb Alliance respects your privacy, and fully complies with the Privacy Act 1988 (Cth) and the Australian Privacy Principles. For further details on how the Pfizer-BMS Alliance (and Pfizer and BMS respectively) collect, store, use and disclose your personal information please see each company's Privacy Policy at www.bmsa.com.au or www.pfizer.com.au. If you wish to enquire about any personal information that Pfizer or BMS hold about you, to cease receiving information from us, request a copy of either company's Privacy Policy, or complain about the processing of your personal information that Pfizer or BMS holds about you, then please write to the Privacy Officer at either company (Pfizer Australia Pty Ltd, Sydney, Australia or email privacyofficer.australia@pfizer.com, or Bristol-Myers Squibb Australia Pty Ltd, 4 Nexus Court, Mulgrave, VIC, 3170 or phone 1800 067 567 or +61 3 8523 4200 or email contact.australia@bms.com). 432AU1800912-05



Bristol-Myers Squibb



Elixir
HEALTHCARE EDUCATION